New Weight-Loss shot BGM1812 enters human testing in china
NCT ID NCT07294235
First seen Dec 29, 2025 · Last updated May 22, 2026 · Updated 20 times
Summary
This early-stage study tests a new drug called BGM1812 in healthy and non-diabetic overweight or obese Chinese adults. The main goal is to check if the drug is safe and tolerable, and to see how it behaves in the body. About 60 participants will receive either the drug or a placebo by injection. This is a Phase 1 trial, so it focuses on safety first, not weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Yunnan University of Chinese Medicine
RECRUITINGKunming, Yunnan, 650000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.